Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Shawn Hingtgen
Univ of North Carolina Chapel Hill, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
Falcon Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The SFIs of the investigator are related to the funded research since the technology being used in the project has been licensed to the company with which the investigator has multiple relationships.
The Institution has determined that since the technology could be further validated as a result of the research, these financial interests could conflict with project.
Engineering stem cell therapies to understand and overcome glioblastoma adaption
Project Narrative Tumoricidal neural stem cells (NSCs) are proven to significantly reduce solid and post-surgical Glioblastoma (GBM) in pre-clinical models. Yet, initial reductions in GBM volumes are not maintained and treatment durability remains a major limitation to this promising strategy. This proposal seeks to investigate the dynamic adaption of GBM to single-agent tumoricidal induced NSC therapy by defining carrier clearance, homing, and tumor resistance throughout GBM recurrence, and modulate novel iNSC treatments to define strategies that effectively address recurrence. These findings are essential for developing NSC-based therapies capable of achieving lasting GBM suppression in future clinical patient testing.
Filed on October 12, 2017.
Tell us what you know about Shawn Hingtgen's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Shawn Hingtgen filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Shawn Hingtgen | Univ of North Carolina Chapel Hill | Conflict of Interest | Falcon Therapeutics | $0 - $4,999 |
| Shawn Hingtgen | Univ of North Carolina Chapel Hill | Conflict of Interest | Falcon Therapeutics | $0 - $4,999 |
| Shawn Hingtgen | Univ of North Carolina Chapel Hill | Conflict of Interest | Falcon Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.